9.93
Xencor Inc stock is traded at $9.93, with a volume of 277.47K.
It is up +7.72% in the last 24 hours and up +17.84% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$9.20
Open:
$9.38
24h Volume:
277.47K
Relative Volume:
0.33
Market Cap:
$710.28M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-3.436
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+12.23%
1M Performance:
+17.84%
6M Performance:
-51.56%
1Y Performance:
-49.97%
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XNCR
Xencor Inc
|
9.98 | 600.68M | 133.62M | -177.37M | 23.50M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.28 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.93 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
574.09 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.08 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-25 | Initiated | William Blair | Outperform |
Dec-12-24 | Initiated | Wells Fargo | Overweight |
Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Apr-16-24 | Reiterated | BTIG Research | Buy |
Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
May-19-23 | Initiated | BofA Securities | Buy |
Dec-06-22 | Initiated | Cowen | Outperform |
Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Jan-21-22 | Initiated | SMBC Nikko | Outperform |
Dec-15-21 | Initiated | H.C. Wainwright | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Mar-04-20 | Initiated | Barclays | Underweight |
Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
Nov-20-19 | Resumed | Guggenheim | Neutral |
Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jun-13-19 | Initiated | Mizuho | Buy |
Apr-12-19 | Initiated | Guggenheim | Buy |
Mar-27-19 | Initiated | Berenberg | Buy |
Mar-15-19 | Initiated | Raymond James | Outperform |
Sep-10-18 | Resumed | BTIG Research | Buy |
Mar-28-18 | Resumed | Leerink Partners | Outperform |
Mar-02-17 | Initiated | Instinet | Neutral |
Mar-02-17 | Reiterated | Wedbush | Outperform |
Oct-04-16 | Initiated | Piper Jaffray | Overweight |
Dec-22-15 | Initiated | Canaccord Genuity | Buy |
Aug-05-15 | Reiterated | MLV & Co | Buy |
Feb-12-15 | Reiterated | Oppenheimer | Outperform |
Jan-28-15 | Reiterated | MLV & Co | Buy |
Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
What analysts say about Xencor Inc. stockConsistent high-yield stocks - Autocar Professional
Is Xencor Inc. a good long term investmentFree AI-Backed Trading Signals - Autocar Professional
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Arizona State Retirement System - Defense World
What drives Xencor Inc. stock priceFree Stock Market Query - Autocar Professional
Xencor Inc. Stock Analysis and ForecastMarket-beating performance - jammulinksnews.com
Why Xencor Inc. stock attracts strong analyst attentionFree Access to Community - Newser
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Teacher Retirement System of Texas - Defense World
Where are the Opportunities in (XNCR) - news.stocktradersdaily.com
What risks could impact Xencor Inc. stock performanceVerified Return Tips - Newser
Principal Financial Group Inc. Grows Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor’s Phase 2 Study on Vudalimab in Prostate Cancer: Key Update and Market Impact - TipRanks
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
How Xencor Inc. stock performs during market volatilityFree Financial Group - Newser
What makes Xencor Inc. stock price move sharplyLow Volatility High Yield Stocks - Newser
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Fed. Circ. Won't Revisit Jepson Claim Ruling In Xencor IP Case - Law360
(XNCR) Investment Analysis - news.stocktradersdaily.com
Closing Figures Unveiled: Xencor Inc (XNCR) Drop -8.18, Closes at 8.31 - DWinneX
Rhumbline Advisers Has $1.74 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling - Defense World
(XNCR) On The My Stocks Page - news.stocktradersdaily.com
Xencor director Gustafson sells shares worth $27,595 - Investing.com Australia
Xencor director Montgomery sells shares worth $20,422 - Investing.com
Xencor Holds Annual Stockholders Meeting on June 12 - TipRanks
Xencor (NASDAQ:XNCR) Trading Up 6.3%Should You Buy? - MarketBeat
USPTO Tells Fed. Circ. Not To Review Ruling In Xencor Case - Law360
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by California State Teachers Retirement System - Defense World
Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Squarepoint Ops LLC - Defense World
When (XNCR) Moves Investors should Listen - news.stocktradersdaily.com
Xencor Inc (NASDAQ: XNCR) Jumps 2.45%: What Could Be On The Way Going Forward? - Stocksregister
Xencor, Inc. (XNCR) Stock Analysis: Exploring a Biotechnology Innovator with 264.58% Potential Upside - DirectorsTalk Interviews
Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com Nigeria
Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress By Investing.com - Investing.com South Africa
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):